1. Raynaud C, Laveran H, Rigal D, Bonicel P. Bacterial contamination of eyedrops in clinical use. J Fr Ophtalmol. 1997; 20:17–24.
2. Rahman MQ, Tejwani D, Wilson JA, et al. Microbial contamination of preservative free eye drops in multiple application containers. Br J Ophthalmol. 2006; 90:139–41.
Article
3. Tasli H, Cosar G. Microbial contamination of eye drops. Cent Eur J Public Health. 2001; 9:162–4.
4. Aslund B, Olson OT, Sandell E. Studies on in-use microbial contamination of eye drops. Acta Pharm Suec. 1978; 15:389–94.
5. Baudouin C, Pisella PJ, Fillacier K, et al. Ocular surface inflammatory changes induced by topical antiglaucoma drugs: human and animal study. Ophthalmology. 1999; 106:556–63.
6. Baudouin C. The pathology of dry eye. Surv Ophthalmol. 2001; 45:11–20.
Article
7. Schwab IR, Abbott RL. Toxic ulcerative keratopathy, An unrecognized problem. Ophthalmology. 1989; 96:1187–93.
8. Butt z, Kaufman D, McNab A, McKelvie P. Drug-induced ocular cicatricial pemphigoid: a series of clinico-pathological reports. Eye. 1998; 12:285–90.
Article
9. Broadway DC, Grierson I, O'Brien C, Hitchings RA. Adverse effects of topical antiglaucoma medications II. Outcomes of filtration surgery. Arch Ophthalmol. 1994; 112:1446–54.
10. Aaberg TM Jr, Flynn HW Jr, Schiffman J, Newton J. Nosocomial acute-onset postoperative endophthalmitis survey. Ophthalmology. 1998; 105:1004–10.
Article
11. Bannerman TL, Rhoden DL, McAllister SK, et al. The source of coagulase-negative staphylococci in the endophthalmitis vitrectomy study. A comparison of eyelid and intraocular isolates using pulsed-field gel electrophoresis. Arch Ophthalmol. 1997; 115:357–61.
12. Madaras-Kelly KJ, Ostergaard BE, Hovde LB, et al. Twenty- four hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model. Antimicrob Agents Chemother. 1996; 40:627–32.
13. Moreau JM, Girgis DO, Hume EBH, et al. Phospholipase A2 in rabbit tears: a host defense against Staphylococcus aureus. Invest Ophthalmol Vis Sci. 2001; 42:2347–54.
14. McCormick CC, Dajcs JJ, Reed JM, et al. The effectiveness of lysostaphin therapy for experimental coagulase-negative Staphylococcus endophthalmitis. Curr Eye Res. 2006; 31:225–30.
15. Baudin C, Pisella PJ, Glodschild M, et al. Ocular surface inflammatory changes induced by topical antiglaucoma drugs. Human and animal studies. Ophthalmology. 1999; 3:556–63.
16. Debbasch C, Pisella PJ, De Saint Jean M, et al. Mitochondrial activity and glutathione injury in apoptosis induced by unpreserved and preserved (3-blockers on Chang conjunctival cells. Invest Ophthalmol Vis Sci. 2001; 42:2525–33.
17. Young TL, Higginbotham EJ, Zou XL, Farber MD. Effects of topical glaucoma drugs on fistulized rabbit conjunctiva. Ophthalmology. 1990; 97:1423–7.
18. Broadway DC, Grierson I, Hitchings RA. Adverse effects of topical antiglaucomatous medications on the conjunctiva. Br J Ophthalmol. 1993; 77:590–6.
Article
19. Ubels JL, McCartney MD, Lantz WK, et al. Effects of preservative-free artificial tear solutions on corneal epithelial structure and function. Arch Ophthalmol. 1995; 113:371–8.
Article
20. Guenoun JM, Baudouin C, Rat P, et al. In vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost and bimatoprost in conjunctiva-derived epithelial cells. Invest Ophthalmol Vis Sci. 2005; 46:2444–50.
Article
21. Ichijima H, Petroll WM, Jester JV, Cavanagh HD. Confocal microscopic studies of living rabbit cornea treated with benzalkonium chloride. Cornea. 1992; 11:221–5.
Article
22. Rucker I, Kettrey R, Bach F, Zeleznick L. A safety test for contact lens wetting solutions. Ann Ophthalmol. 1972; 4:1000–6.
23. Cha SH, Lee JS, Oum BS, Kim CD. Corneal epithelial cellular dysfunction from benzalkonium chloride in vitro. Clin Experiment Ophthalmology. 2004; 32:180–4.
24. Bin T, Kulshreshtha AK, Al-shakhshir R, Hem SL. Adsorption of benzalkonium chloride by filter membranes: mechanisms and effect of formulation and processing parameters. Pharm Dev Technol. 1999; 4:151–65.
Article